TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01737931
Drug: Topical antihistamine (Diphenhydramine)
Normalized name: Ahist Antihistamine
DrugBank: Histamine (DB05381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: for SPM 962: 1 mg/24h patch for 48 hours as Acceleration period, then 2 mg/24h patch to the other site for 24 hours as Dose-escalation period, for antihistamine: twice daily administration of Diphenhydramine (10 mg/g cream) to the application sites after the patch removal
Study: NCT00616850
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine 1.33mg/kg/hr continuous IV infusion following induction of general anesthesia to 24 hours postoperatively.
Study: NCT03023566
Drug: Dotarem
Normalized name: Dotarem
DrugBank: Gadoteric acid (DB09132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dotarem at dose of 0.1 mmol/kg of body weight (routine/standard of care)
Study: NCT00308711
Drug: Misoprostol vaginal insert 100 mcg
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrogel polymer intravaginal insert with retrieval system. One insert is to remain in the posterior fornix of the vagina until removed for one of the following conditions: onset of active labor; maternal/fetal complication, e.g. non-reassuring fetal heart rate. Record if the insert falls out prior to meeting one of the first two criteria. In no case is the insert to remain in place longer than 24h.
Study: NCT00308711
Drug: Misoprostol vaginal insert 50 mcg
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrogel polymer intravaginal insert with retrieval system. One insert is to remain in the posterior fornix of the vagina until removed for one of the following conditions: onset of active labor; maternal/fetal complication, e.g. non-reassuring fetal heart rate. Record if the insert falls out prior to meeting one of the first two criteria. In no case is the insert to remain in place longer than 24h.
Study: NCT01880307
Drug: Infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02167256
Drug: AZD0530 100mg daily
Normalized name: glecaprevir
DrugBank: Glecaprevir (DB13879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All patients in experimental group (50%) will be started on 100mg AZD0530 daily
Study: NCT01466192
Drug: MP-424 (generic name:Telaprevir)
Normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 750mg q8h for 12 weeks
Study: NCT01466192
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 - 1000 mg/day based on body weight for 24 weeks
Study: NCT01466192
Drug: Peginterferon alfa-2b
Normalized name: Peginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.5mcg/kg/week for 24 weeks
Study: NCT01666223
Drug: Colesevelam
Normalized name: Colesevelam
DrugBank: Colesevelam (DB00930)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colesevelam 3750 mg dissolved in 100 ml saline, administered in a feeding tube at time = 0.
Study: NCT00414388
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400mg twice daily
Study: NCT03467425
Drug: LAMA
Normalized name: Alamag
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LAMA as prescribed by the physician.
Study: NCT03467425
Drug: LABA
Normalized name: Malabar Nut Leaf
DrugBank: Labafenogene marselecobac (DB17618)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LABA as prescribed by the physician.
Study: NCT01243346
Drug: Crenolanib besylate (CP-868,596-26), Dose: 140mg BID
DrugBank: Crenolanib (DB11832)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly potent inhibitor of both PDGFR receptors alpha and beta
Study: NCT01543347
Drug: Temocillin
Normalized name: temocillin
DrugBank: Temocillin (DB12343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment
Study: NCT00862784
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 85 milligrams/square meter (mg/m²) intravenous infusion over 2 hours on Day 1
Study: NCT00862784
Drug: Folinic acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m² intravenous infusion over 2 hours on Day 1
Study: NCT00862784
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m² intravenous bolus injection over 2-4 minutes, immediately following folinic acid infusion
Study: NCT00862784
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2400 mg/m² intravenous continuous infusion over 46 hours immediately following bolus 5-FU on Days 1 and 2
Study: NCT00712296
Drug: ASHMI 4
Normalized name: JUNIPERUS ASHEI POLLEN
DrugBank: Juniperus ashei pollen (DB10460)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 capsules orally twice a day
Study: NCT00712296
Drug: ASHMI 12
Normalized name: JUNIPERUS ASHEI POLLEN
DrugBank: Juniperus ashei pollen (DB10460)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 capsules orally twice a day
Study: NCT00245765
Drug: Certolizumab Pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * Pharmaceutical Form: solution for injection in pre-filled syringe~* Route of Administration: subcutaneous use
Study: NCT01588912
Drug: Telbivudine
Normalized name: Telbivudine
DrugBank: Telbivudine (DB01265)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: If virologic response, which means HBV DNA \< 50 IU/mL, is shown at 24 weeks, telbivudine monotherapy is maintained and in the event that virologic response is not shown, tenofovir add-on therapy is done
Study: NCT01588912
Drug: Tenofovir
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: If virologic response, which means HBV DNA \< 50 IU/mL, is shown at 24 weeks, telbivudine monotherapy is maintained and in the event that virologic response is not shown, tenofovir add-on therapy is done
Study: NCT01588912
Drug: Entecavir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maintain the entecavir through the study period
Study: NCT02084628
Drug: Gadoxetate disodium (Eovist/Primovist, BAY86-4873)
Normalized name: Gadoxetate Disodium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants to receive single dose of Eovist/Primovist as a manual injection at a dose of 0.1 milliliter per kilogram (mL/kg) body weight (BW) (0.025 millimole \[mmol\]/kg BW), followed by a flush of at least 5 mL saline (sodium chloride 0.9 percent \[%\] solution) manually.
Study: NCT04150224
Drug: PBTZ169 960 mg SD
Normalized name: Alphanine SD
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once a day fasted
Study: NCT04150224
Drug: PBTZ169 1280 mg SD
Normalized name: Alphanine SD
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once a day fasted
Study: NCT00569686
Drug: lovaza
Normalized name: Lovaza
DrugBank: Omega-3-acid ethyl esters (DB09539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lovaza 4 gm po daily
Study: NCT00473915
Drug: fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: corticosteroid nasal spray
Study: NCT00352612
Drug: cephalexin
Normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cephalexin suspension or tablets, 40mg/kg/day, given by mouth, divided TID, for 7 days
Study: NCT00528528
Drug: Telaprevir
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oval tablets containing 375 mg of telaprevir for oral administration.
Study: NCT00528528
Drug: Peg-IFN-alfa-2a
Normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solution containing Peg-IFN alfa2a for subcutaneous injection in a pre-filled syringe.
Study: NCT00528528
Drug: Peg-IFN-alfa-2b
Normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Powder containing Peg-IFN-alfa-2b and solvent for solution for subcutaneous injection in a pre-filled pen.
Study: NCT00528528
Drug: Ribavirin (RBV) tablet
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablets containing 200 mg RBV for oral administration.
Study: NCT00528528
Drug: Ribavirin (RBV) capsule
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capsules containing 200 mg RBV for oral administration.
Study: NCT01321801
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Preoperative administration of pregabalin 600mg
Study: NCT03597516
Drug: RP-G28
Normalized name: RP-72
DrugBank: RP-72 (DB17156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: powder for reconstitution for oral administration
Study: NCT00184015
Drug: Bevacizumab and Bortezomib
Normalized name: Bortezomib
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 15 mg/kg on day 1 with Bortezomib 1.0 or 1.3 mg/m2 on days 1, 4, 8 and 11 every 21 days
Study: NCT00184015
Drug: Bevacizumab and Bortezomib
Normalized name: Bortezomib
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 15 mg/kg on day 1 with Bortezomib 1.6 or 1.8 mg/m2 on days 1 and 8 every 21 days
Study: NCT00417443
Drug: Clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00401011
Drug: Perifosine
Normalized name: Perifosine
DrugBank: Perifosine (DB06641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase I: Patients will receive daily perifosine (doses 50 mg/m2 or 100 mg/m2) at bedtime.~Phase II: All patients will receive daily perifosine at bedtime. Patients will be evaluated every 3 weeks.
Study: NCT00401011
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Phase I: Patients will receive 1 mg/m2 or 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks. Phase II: Patients will receive bortezomib on days 1,4,8 and 11 every 3 weeks.
Study: NCT00401011
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Phase II: If the patient shows progressive disease after 3 weeks, dexamethasone 20 mg will be added to perifosine and bortezomib on days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 18, and 19 to perifosine at bedtime and bortezomib IV on days 1, 4, 8, and 11 q 21 days.
Study: NCT00701129
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered as IV infusion.
Study: NCT02412631
Drug: lorcaserin
Normalized name: Lorcaserin
DrugBank: Lorcaserin (DB04871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lorcaserin is an FDA-approved weight loss medication for overweight and obese patients
Study: NCT02412631
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chantix is an FDA approved medication for smoking cessation
Study: NCT02299050
Drug: Cycloset
Normalized name: Cycloset
DrugBank: Bromocriptine (DB01200)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bromocriptine QR 0.8 mg tablet 0.8 mg/day with dose increased to a maximum of 3.2 mg/day or as tolerated to a minimum of 2.4 mg/day Other names: Cycloset, B-QR
Study: NCT00723957
Drug: Ixabepilone, 32 mg/m^2
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous (IV) solutions, ixabepilone, 32 mg/m\^2
Study: NCT00723957
Drug: Paclitaxel, 200 mg/m^2
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV solutions, paclitaxel, 200 mg/m\^2
Study: NCT00723957
Drug: Carboplatin (area under the concentration curve [AUC] 6)
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin (AUC 6) day 1, every 21 days, 6 cycles
Study: NCT02940691
Drug: Grazoprevir/elbasvir
DrugBank: Elbasvir (DB11574)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Grazoprevir/elbasvir (100mg/50mg) once daily for 12 weeks.
Study: NCT00347152
Drug: Divalproex
Normalized name: DIVALPROEX
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Divalproex, 8-20% taper
Study: NCT04181346
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: antipsychotic
Study: NCT01753453
Drug: Plerixafor
Normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 240mcg/kg, solution, subcutaneous injection
Study: NCT01753453
Drug: Granulocyte-colony stimulating factor (G-CSF)
Normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mcg/kg, solution, subcutaneous injection
Study: NCT02177266
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine 0.6mg bid will be given to study participants randomized to the study drug arm beginning at 48-72 hours prior to the planned cardiac surgery and then continued for a total of 30 days.
Study: NCT00755079
Drug: extended release beta-2 adrenergic agonist
Normalized name: HUMAN INTERFERON BETA-2
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol extended release belongs to a class of drugs known as bronchodilators. It works in the airways by opening breathing passages and relaxing muscles.
Study: NCT03019627
Drug: NGF
Normalized name: Hemoglobin Shuangfeng
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye Drop 20 μg/mL
Study: NCT01367808
Drug: vorikonazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The subject will be given vorikonazole twice a day for 5 days prior to the study. The dose will be 400 mg twice a day on day one ans 200 mg twice a day on days 2-5.
Study: NCT01367808
Drug: posakonazole
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The subjects will be given posaconazole 400 mg twice a day for 5 days prior to the study.
Study: NCT04038489
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 325 mg aspirin daily during AC-T chemotherapy
Study: NCT04038489
Drug: Tamoxifen Pill
Normalized name: tamoxifen Pill
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (either 20 mg daily or 10 mg twice a day) during AC-T chemotherapy
Study: NCT04038489
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 80 mg/m2 or 175 mg/m2 based on provider preference. Given by IV after completion of doxorubicin/cyclophosphamide therapy
Study: NCT00546715
Drug: Daclatasvir
Normalized name: Daclatasvir
DrugBank: Daclatasvir (DB09102)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral Solution, Oral, Single Dose
Study: NCT00418691
Drug: IR Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg by mouth (PO) twice daily x 4 Weeks
Study: NCT00418691
Drug: Modafinil
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg PO Once Daily x 4 Weeks
Study: NCT00418691
Drug: SR Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 18 mg PO Once Daily x 4 Weeks
Study: NCT01369875
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/m\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days (days -5 to -1)
Study: NCT00004436
Drug: leuprolide
Normalized name: Leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00004436
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01993108
Drug: Methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One dose 40mgs of methylphenidate one hour before fMRI scanning.
Study: NCT01993108
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One dose 40mgs of naltrexone one hour before fMRI scanning.
Study: NCT00004144
Drug: bryostatin 1
Normalized name: Bryostatin 1
DrugBank: Bryostatin 1 (DB11752)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00004144
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00628290
Drug: Cannabidiol
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsules, 3 times daily, 200 mg, 4 weeks
Study: NCT00628290
Drug: Amisulpride
Normalized name: Amisulpride
DrugBank: Amisulpride (DB06288)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsules, 3 times daily, 200 mg, 4 weeks
Study: NCT00231608
Drug: topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00577122
Drug: Medroxyprogesterone progesterone acetate (MPA)
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg po daily
Study: NCT03019276
Drug: TQ-B3101
Normalized name: TQS-168
DrugBank: TQS-168 (DB18108)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating doses of TQ-B3101 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 100 mg to 500 mg/day administered either once or twice a day. A treatment cycle is considered to be 28 days .
Study: NCT02897596
Drug: Grazoprevir 100 mg/d 8 weeks
DrugBank: Grazoprevir (DB11575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with 1b HCV genotype will be received treatment with Grazoprevir (100 mg) during 8 weeks.
Study: NCT02897596
Drug: Elbasvir 50 mg/d 8 weeks
DrugBank: Elbasvir (DB11574)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with 1b HCV genotype will be received treatment with Elbasvir (50mg) during 8 weeks.
Study: NCT02897596
Drug: Grazoprevir 100 mg/d 12 weeks
DrugBank: Grazoprevir (DB11575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with 1a or 4 HCV genotype will be received treatment with Grazoprevir (100 mg) during 12 weeks.
Study: NCT02897596
Drug: Elbasvir 50 mg/d 12 weeks
DrugBank: Elbasvir (DB11574)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with 1a or 4 HCV genotype will be received treatment with Elbasvir (50mg) during 12 weeks.
Study: NCT03025724
Drug: Levulan Kerastick
Normalized name: Levulan Kerastick
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention group subjects will undergo a surgical excision of the tumor. Then a clear transparency film will be used to trace the clinical margins of the lesion, as well as any other distinctive skin markings such as nevi or birthmarks. Subjects will then undergo the study procedure where the area to be treated will be swabbed with an alcohol wipe and allowed to dry. Next, the investigator will apply topical 20% 5-ALA (Levulan Kerastick; DUSA Pharmaceuticals) to the SCCis. Then, the area will be occluded with Tegaderm film for 3 hours.
Study: NCT03393026
Drug: Lurasidone
Normalized name: Lurasidone
DrugBank: Lurasidone (DB08815)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lurasidone 40-160 mg/day for 6 weeks
Study: NCT02953821
Drug: Acthar Gel
Normalized name: Acthar Gel
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mL (80 Units) given by a shot under the skin (via subcutaneous injection)
Study: NCT00782210
Drug: Olodaterol (BI1744)
Normalized name: Olodaterol
DrugBank: Olodaterol (DB09080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison of low and high doses on efficacy and safety in COPD patients
Study: NCT04447092
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 1000 mg/m2 iv D1, 8, 15 (every 4 weeks)
Study: NCT04447092
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel 125 mg/m2 iv D1, 8, 15 (every 4 weeks)
Study: NCT04447092
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab ( 200 ) mg iv D1 (every 3 weeks)
Study: NCT04447092
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 65 mg/m2 iv over 2 hours D1 (every 2 weeks)
Study: NCT04447092
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan 140 mg/m2 iv over 1.5 hours D1 (every 2 weeks)
Study: NCT03244657
Drug: conbercept ophthalmic injection （0.5mg）
DrugBank: Conbercept (DB12460)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The target eye receives intravitreal injection of 0.5mg conbercept ophthalmic injection once every 12 weeks; if a subject meets additional drug administration criteria within 12 weeks between treatments, the subject can receive additional injection treatment
Study: NCT01018420
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: two 0.6 mg capsules (1.2 mg dose) followed by an additional 0.6mg capsule every hour for 6 additional doses
Study: NCT01018420
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg capsule at the 6 hour point
Study: NCT00964808
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Start: Day 0 (T=0), 10 micrograms/t until the day of discharge from the Hospital. New plaster at T= 7 days.
Study: NCT00964808
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Start: 10 hours (+/- 2 hours) after the operation. Dosage: 10 mg \* 2 pr. day until time to discharge from the Hospital or latest at day 12.
Study: NCT00265616
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: liquid, mg/kg.h, titrated after EEG
Study: NCT00265616
Drug: thiopental/pentobarbital
DrugBank: Pentobarbital (DB00312)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: liquid, mg/kg.h, titrated after EEG
Study: NCT00654381
Drug: BI 1356
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/daily